|Global Infectious Disease Therapeutics Market 2019-2023 with Profiles of Major Players - AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi - ResearchAndMarkets.com|
|Wednesday, 09 January 2019 23:06|
Jan. 10, 2019 09:23 UTC
Global Infectious Disease Therapeutics Market 2019-2023 with Profiles of Major Players - AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)-- The "Global Infectious Disease Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The infectious disease therapeutics market will register a CAGR of over 4% by 2023.
Development of novel drugs to drive growth in the market. There has been an increase in the R&D of novel drugs for the treatment of infectious diseases.
Increasing prevalence of infectious diseases
There has been an increase in the prevalence of infectious diseases due to climate variability. This is expected to be a major driver of the market growth during the forecast period.
Availability of counterfeit drugs
Counterfeit drugs are available in low-income and developing countries. These drugs are widely available because of insufficient regulations and manufacturing control.
The market appears to be fragmented and with the presence of several companies including Merck and Sanofi, the competitive environment is quite intense. Factors such as the development of novel drugs and the increase in the prevalence of infectious diseases, will provide considerable growth opportunities to infectious disease therapeutics manufactures.
AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi are some of the major companies covered in this report.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
For more information about this report visit https://www.researchandmarkets.com/research/9mqnvj/global_infectious?w=4
Source: Research and Markets